MAPT and supranuclear palsy, progressive, 1: The goal of the present study was to elucidate the distribution of [11C]PBB3‐PET–detectable tau lesions in PSP patients, followed by the localization of tau tracer accumulations correlated with the severity of clinical symptoms.